Phreesia, Inc. (NYSE:PHR) General Counsel Sells $60,961.50 in Stock

Phreesia, Inc. (NYSE:PHR) General Counsel Allison C. Hoffman sold 2,622 shares of the stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $23.25, for a total transaction of $60,961.50. Following the sale, the general counsel now owns 123,075 shares of the company’s stock, valued at $2,861,493.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Phreesia Price Performance

Shares of NYSE:PHR opened at $24.68 on Friday. Phreesia, Inc. has a twelve month low of $12.05 and a twelve month high of $29.16. The firm has a market capitalization of $1.42 billion, a PE ratio of -11.37 and a beta of 0.93. The company has a quick ratio of 1.77, a current ratio of 1.77 and a debt-to-equity ratio of 0.03. The company has a 50-day moving average price of $23.72 and a two-hundred day moving average price of $22.75.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. nVerses Capital LLC grew its stake in shares of Phreesia by 76.5% during the second quarter. nVerses Capital LLC now owns 3,000 shares of the company’s stock valued at $64,000 after buying an additional 1,300 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Phreesia by 5,462.3% during the 4th quarter. Russell Investments Group Ltd. now owns 3,838 shares of the company’s stock valued at $89,000 after purchasing an additional 3,769 shares in the last quarter. EntryPoint Capital LLC bought a new position in Phreesia in the first quarter worth $169,000. Quadrature Capital Ltd bought a new position in shares of Phreesia in the 1st quarter worth about $202,000. Finally, Lombard Odier Asset Management USA Corp purchased a new stake in Phreesia in the second quarter worth about $202,000. Institutional investors own 92.10% of the company’s stock.

Analysts Set New Price Targets

PHR has been the topic of a number of recent analyst reports. Needham & Company LLC reissued a “buy” rating and issued a $29.00 price objective on shares of Phreesia in a research note on Thursday, September 5th. Truist Financial boosted their price target on shares of Phreesia from $29.00 to $31.00 and gave the company a “buy” rating in a research note on Friday, September 6th. JPMorgan Chase & Co. raised their target price on Phreesia from $27.00 to $28.00 and gave the company an “overweight” rating in a report on Monday, September 9th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $23.00 price objective on shares of Phreesia in a report on Thursday, September 5th. Finally, Robert W. Baird increased their price objective on shares of Phreesia from $31.00 to $34.00 and gave the company an “outperform” rating in a research note on Friday, September 6th. One analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $29.42.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.